Melika Abrishami

Ms. Melika Abrishami


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2025 in Antonie van Leeuwenhoek
Verified
Journal Article
Closed access
PDF file
MAMelika Abrishami
Melika Abrishami
MSMohadeseh Sabouri
Mohadeseh Sabouri
FJFereshte Joneidi
Fereshte Joneidi
ZHZahra Haghshenas
Zahra Haghshenas
GKghazaleh khalili-tanha
ghazaleh khalili-tanha
ENElham Nazari
Elham Nazari

8 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YAYashmin Afshar
Yashmin Afshar
AGAli Goli
Ali Goli
MAMelika Abrishami
Melika Abrishami
Resistant mechanisms to venetoclax, a selective BCL-2 inhibitor approved for hematological malignancies, are frequently mediated by the G101V mutation in BCL-2. Sonrotoclax illustrates superior potency against both wild-type and G101V-mutated BCL-2, yet the mechanistic basis remains unclear. This study employed computational methods to investigate the binding dynamics of both inhibitors. Structures were predicted with AlphaFold, refined via molecular dynamics simulations (MDS), and ligands were docked with AutoDock Vina. Four systems were subjected to triplicate 200 ns MDS, with analyses including RMSD, RMSF, buried surface area, protein-ligand interaction fingerprint, and MM/GBSA binding free energies. Results indicate venetoclax exhibits progressive dissociation from G101V BCL-2, with elevated RMSD, reduced buried surface area, and increased unbound states. In contrast, Sonrotoclax maintains a steady correlation, shows persistence with entropy-enthalpy compensation, displays negligible unbound time, higher binding free energies, and constant van der Waals anchors. Having all these results in mind, a "Dynamic Blockade" hypothesis is proposed, where Sonrotoclax's flexibility enables sustained BH3 groove occupancy, blocking pro-apoptotic BH3-only proteins and overcoming allosteric perturbations induced by G101V. This mechanistic perspective proposes the optimal approach for designing resilient inhibitors to accelerate drug repurposing and development in oncology.